TITLE:
Management of Post-Traumatic Stress (PTSD) Dementia and Other Neuro-Degenerative Disease with Photo-Medicine: Clinical Experience and Case Studies
AUTHORS:
William Stephan, Ronald Aung Din, Louis J. Banas, John Thomas, Carolyn Kochert, Randy J. Lamartiniere, Carol Spooner, Gerard Pesca, Dudley Chewning Eddy
KEYWORDS:
Photobiomodulation, Photo Medicine (PM), Neuroregeneration, Neuro-Degenerative Disease, Small Vessel Disease (SVD)
JOURNAL NAME:
Open Journal of Psychiatry,
Vol.7 No.4,
October
20,
2017
ABSTRACT: Objective: Photobiomodulation (also known as Low Level Laser. LLLT or Cold Laser; Photo Medicine (PM)) has been a vital adjunct therapy in our clinical practice over 5 years, observations of improvement in cognition and personality were noted in several patients. As a result, selected patients with Alzheimer’s Disease, vascular dementia, post-traumatic brain injury and other neuro-degenerative diseases were treated at clinical practices in Buffalo, New York; Sarasota, Florida; Lafayette, Indiana; Phoenix, Az., and Baton Rouge, La. Over 60 patients were treated with an average of 4 times over an 8-day period all reported/exhibited improvement in their condition, except that two men who were in their seventies were in robust health but had no short-term memory and no improvement was observed. However, Theralase has developed a more efficacious system which will be more efficacious, due to increased power for ATP activation. Method: Over 150 patients with the above conditions were treated in various areas (depending on diagnosis) including the prefrontal cortex, temporal lobe, Hippocampus, and Circle of Willis for duration of two and one-half minutes every 48 hours for 5 - 6 treatments. We utilized the Theralase multi-probe (905 nm/660 nm) at 60 miliwatts. It utilizes 5 - 905 nm near infra-red diodes and 4 infra-red 660 laser diodes with a peak power of 50,000 milliwatts at peak and pulse duration of 200 nanoseconds [1]. The PTSD patients were evaluated utilizing the co-occurring disorders program screening and assessment form. Conclusion: Dementia patients exhibited varying degrees of improvement in cognitive function and personality, leading to improved quality of life and decreased caregiver burden. PTSD patients’ improvement was objectively measured by formal neuropsychological testing utilizing the form. All PTSD patients scored no emotional problems after 3 - 5 treatments and all experienced overall sense of well-being. One experienced return of ability to smell he had not had for 5 years. Similar results were reported in a Japanese study where 15 patients were followed for a year. This non-invasive and non-systemic modality of therapy could play a key role in treating progressive neurodegenerative conditions, improving quality of life, and reducing health care costs.